Michael O'donnell

A complementary route to diaminopyrimidines through regioselective SNAr amination reactions

J. Charrier, Michael O'donnell, 2015 .

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

David Bebbington, Michael O'Donnell, Damien Fraysse, 2009, Bioorganic & medicinal chemistry letters.

Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

P. Reaper, J. Pollard, M. Mortimore, 2011, Journal of medicinal chemistry.

Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.

P. Reaper, J. Golec, M. Griffiths, 2019, Journal of medicinal chemistry.

2-Chloro-4-tetrafluorophenoxypyrimidine: a versatile reagent for C-2 prior to C-4 functionalizations

J. Charrier, Michael O'donnell, 2016 .

2-Chloro-4-tetrafluorophenoxypyrimidine: A Versatile Reagent for C-2 Prior to C-4 Functionalizations.

J. Charrier, Michael O'donnell, 2016 .

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

M. Mortimore, D. Kay, D. Bebbington, 2009, Bioorganic & medicinal chemistry letters.

Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

P. Reaper, M. Mortimore, D. Kay, 2011, Journal of medicinal chemistry.